Heterogeneity in the vasorelaxing effect of nicorandil on dog epicardial coronary arteries: Comparison with other NO donors

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 6, 1997, Pages 772-779

  Matsumoto, Tetsuya ^a   Takahashi, Masayuki ^a   Omura, Tomoko ^a   Takaoka, Atsushi ^a   Liu, Quan ^a   Nakae, Ichiro ^a   Kinoshita, Masahiko ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Coronary arteries; Cromakalim; Dog; Nicorandil; Nitroglycerin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CROMAKALIM; CYCLIC GMP; GLIBENCLAMIDE; GLYCERYL TRINITRATE; METHYLENE BLUE; NICORANDIL; NITRIC OXIDE; OXYHEMOGLOBIN; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORONARY ARTERY; CORONARY VASCULAR RESISTANCE; DOG; ENZYME ACTIVITY; GENETIC HETEROGENEITY; HEART FAILURE; HEART MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; VASODILATATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BENZOPYRANS; CORONARY VESSELS; CROMAKALIM; CYCLIC GMP; DOGS; FEMALE; GLYBURIDE; MALE; METHYLENE BLUE; MOLSIDOMINE; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NIACINAMIDE; NICORANDIL; NITRIC OXIDE; NITROGLYCERIN; NITROPRUSSIDE; OXYHEMOGLOBINS; PYRROLES; VASODILATOR AGENTS;

EID: 0030805104     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199706000-00010     Document Type: Article

References (38)

1. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989;63:18J-24J.
2. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990;4:1075-88.
3. Kinoshita M, Nishikawa S, Sawamura M, et al. Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris. Am J Cardiol 1986;58:733-8.
4. Döring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992;20(suppl 3):S74-81.
5. Tsutamoto T, Kinoshita M, Nakae I, et al. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. Am Heart J 1994;127:866-73.
6. Taira N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. J Cardiavasc Pharmacol 1987;10(suppl 8):S1-9.
7. Kukovetz WR, Holzmann S, Braida C, Poch G. Dual mechanism of the relaxing effect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization. J Cardiovasc Pharmacol 1991;17:627-33.
8. Meisheri KD, Cipkus-dubray LA, Hosner JM, Khan SA. Nicorandil-induced vasorelaxation: functional evidence for K channel-dependent and cyclic GMP-dependent components in a single vascular preparation. J Cardiovasc Pharmacol 1991;17:903-12.
9. Feelisch M. Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. Eur Heart J 1993;14(suppl 1):123-32.
10. Harrison DG, Bates JN. The nitrovasodilators: new ideas about old drugs. Circulation 1993;87:1461-7.
11. Winbury MM, Howe BB, Hefner MA. Effect of nitrates and other coronary dilators on large and small coronary vessels: a hypothesis for the mechanism of action of nitrates. J Pharmacol Exp Ther 1969;168:70-95.
12. Zhang J, Somers M, Cobb FR. Heterogenous effects of nitroglycerin on the conductance and resistance coronary arterial vasculature. Am J Physiol 1993;264:H1960-8.
13. Sellke FW, Myers PR, Bates JN, Harrison DG. Influence of vessel size on the sensitivity of porcine coronary microvessels to nitroglycerin. Am J Physiol 1990;258:H515-20.
14. Sellke FW, Tomanek RJ, Harrison DG. L-Cysteine selectively potentiates nitroglycerin-induced dilation of small coronary microvessels. J Pharmacol Exp Ther 1991;258:365-9.
15. Nagao T, Illiano S, Vanhoutte PM. Heterogeneous distribution of endothelium-dependent relaxations resistant to nitro-L-arginine in the arterial tree of the rat. Am J Physiol 1992;263:H1090-4.
16. Imagawa J, Akima M, Nabata H, Taira N. Spasmolytic action of nicorandil in canine conductive coronary arteries in vivo is not modified by glibenclamide. J Cardiovasc Pharmacol 1992;19: 108-14.
17. Nakae I, Liu Q, Hashimoto K, Sugimoto Y, Tsutamoto T, Kinoshita M. Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs. Cardiovasc Drugs Ther 1994;8:137-45.
18. + channel in insulin secreting cells. Biochem Biophys Res Commun 1987;146:21-5.
19. Martin W, Villani GM, Jothianandan D, Furchgott RF. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985;232:708-16.
20. Gruetter CA, Kadowitz PJ, Ignarro LJ. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Can J Physiol Pharmacol 1981;59:150-6.
21. Toda N. The action of vasodilating drugs on isolated basilar, coronary and mesenteric arteries of the dog. J Pharmacol Exp Ther 1974;191:139-46.
22. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM, ed. Mechanism of vasodilatian. Vol IV. New York: Raven Press, 1988:401-14.
23. Fam WM, McGregor M. Effect of nitroglycerin and dipyridamole on regional coronary resistance. Circ Res 1968;22:649-59.
24. Sato K, Kanatsuka H, Sekiguchi N, et al. Effect of an ATP-sensitive potassium channel opener, levcromakalim, on coronary arterial microvessels in the beating canine heart. Cardiovasc Res 1994; 28:1780-6.
25. Komaru T, Lamping KG, Eastham CL, Dellsperger KC. Role of ATP-sensitive potassium channels in coronary microvascular autoregulatory responses. Circ Res 1991;69:1146-51.
26. Samaha FF, Heinaman W, Ince C, Fleming J, Balaban RS. ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo. Am J Physiol 1992;262:C1220-7.
27. 2, and adenosine. Am J Physiol 1972;223:223-8.
28. Giudicelli JF, Drieu La Rochelle C, Berdeaux A. Effects of cromakalim and pinacidil on large epicardial and small coronary arteries in conscious dogs. J Pharmacol Exp Ther 1990;255:836-42.
29. Berdeaux A, Drieu La Rochelle C, Richard V, Giudicelli JF. Differential effects of nitrovasodilators, K-channel openers, and nicorandil on large and small coronary arteries in conscious dogs. J Cardiovasc Pharmacol 1992;20(suppl 3):S17-21.
30. Miwa A, Kaneta S, Motoki K, et al. Vasorelaxant mechanism of KRN2391 and nicorandil in porcine coronary arteries of different sizes. Br J Pharmacol 1993;109:632-6.
31. Waldman SA, Rapoport RM, Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 1984;259:14332-4.
32. Kurz MA, Lamping KG, Bates JN, Eastham CL, Marcus ML, Harrison DG. Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res 1991;68:847-55.
33. Kowaluk EA, Seth P, Fung H-L. Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle. J Pharmacol Exp Ther 1992;262:916-22.
34. Kukovetz WR, Holzmann S. Mechanism of vasodilation by molsidomine. Am Heart J 1985;109:637-40.
35. Matsumoto T, Okamura T, Kinoshita M, Toda N. Interactions of nitrovasodilators and atrial natriuretic peptide in isolated dog coronary arteries. Eur J Pharmacol 1993;237:31-7.
36. Matsumoto T, Takahashi M, Nakae I, Kinoshita M. Vasorelaxing effect of S-nitrosocaptopril on dog coronary arteries: no cross-tolerance with nitroglycerin. J Pharmacol Exp Ther 1995;275: 1247-53.
37. Satoh K, Yamada H, Taira N. Differential antagonism by glibenclamide of the relaxant effects of cromakalim, pinacidil and nicorandil on canine large coronary arteries. Naunyn-Schmiedebergs Arch Pharmacol 1991;343:76-82.
38. Hashimoto K, Kinoshita M, Ohbayashi Y. Coronary effects of nicorandil in comparison with nitroglycerin in conscious dogs. Cardiovasc Drugs Ther 1991;5:131-8.